MEDPACE HOLDINGS INC (MEDP) Stock News
NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD
MEDP Latest News, Press Relases and Analysis
2 Unpopular Stocks that Deserve Some Love and 1 to Turn Down
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Medpace Holdings, Inc. (MEDP): A Bull Case Theory
We came across a bullish thesis on Medpace Holdings, Inc. (MEDP) on Substack by Compound & Fire. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc. (MEDP)’s share was trading at $305.98 as of May 19th. MEDP’s trailing and forward P/E were 23.36 and 24.88 respectively according to Yahoo Finance. Medpace Holdings […]
Mentions: VZ
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally.
CON vs. MEDP: Which Stock Is the Better Value Option?
CON vs. MEDP: Which Stock Is the Better Value Option?
Mentions: CON
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
Style Box ETF report for JSMD
Is Healthcare Losing the Status of Safe Haven? ETFs in Focus
Healthcare stocks face new risks under Trump, despite their usual defensive reputation.
Mentions: PFE
CON or MEDP: Which Is the Better Value Stock Right Now?
CON vs. MEDP: Which Stock Is the Better Value Option?
Mentions: CON
Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified
The company's bookings missed expectations for the fifth consecutive quarter. Investors are questioning its "path forward."
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
‘No way’ US can recoup lost China container imports: Analyst
President Trump’s China trade embargo is projected to devastate containerized shipments moving through U.S. ports. The post ‘No way’ US can recoup lost China container imports: Analyst appeared first on FreightWaves.
Trump tariffs, research funding cuts pressure smaller health stocks
Healthcare used to be considered a safe, constant growth sector, weighted heavily in some 401(k)s. But it isn't immune to current market volatility.
Medpace Holdings, Inc. Reports First Quarter 2025 Results
Factors That Drive Kinsale Capital Group’s (KNSL) Growth
Giverny Capital Asset Management, LLC, an investment management company, recently published its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The portfolio returned -3.39% in the quarter, compared to a -4.27% return for the S&P 500 Total Return Index. For the year ended March 31, 2025, the fund returned 1.75% […]
Here’s Why Investors Rotated Away from Xometry (XMTR)
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Changing trade, monetary, and fiscal policies increased volatility in US stocks. The emergence of artificial intelligence (AI) models from China added to the uncertainty. Against this backdrop, […]
Here’s Wedgewood Partners’ Investment Thesis for United Rentals (URI)
Wedgewood Partners, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, Wedgewood Composite’s net return was -6.3% compared to the Standard & Poor’s -4.3%, the Russell 1000 Growth Index’s -10.0% and the Russell 1000 Value Index’s 2.1% return for the same […]
What Makes Medpace Holdings (MEDP) an Investment Bet?
Investment management company Vulcan Value Partners recently released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The first quarter experienced the return of volatility. The companies’ management teams expressed a more cautious view following the recent election. Optimism has given way to uncertainty about tariffs and potential impacts on earnings, inflation, and […]
Best brokers for bonds in 2025
Here are our top picks for the best online brokers for bonds.
Brazil's Gol postpones deadline for proposed $1.9 billion financing
SAO PAULO (Reuters) -Brazilian airline Gol has postponed the deadline for investors to analyze proposals for a $1.9 billion financing, it said in a statement on Tuesday, citing the volatility created by tariffs imposed by U.S. President Donald Trump. The deadline for the so-called "exit financing" from the firm's judicial reorganization process was postponed from April 19 to May 15, the statement said. Potential Gol investors were notified about the extension by Seabury Securities, which acts as the investment bank for the company due to "significant fluctuations" caused by the tariffs announced by Trump on April 2, Gol said.
Retirement planning: What it is and 4 key first steps to get started
Ready to start planning for retirement? Here’s what you should know.
Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit. A successful company that fits this billing is Medpace (NASDAQ: MEDP), a leading clinical contract research organization.
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
LVS Advisory Sold Icon Plc (ICLR) After Identifying Flaws in its Investment Thesis
LVS Advisory, a New York City-based full-service investment firm, recently released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter of 2025, the LVS Event-Driven portfolio returned 0.8% (net of fees) and the LVS Growth Portfolio delivered 0.3%, net of all fees and expenses. This compared […]